Skip to main content
Erschienen in: International Journal of Colorectal Disease 9/2014

01.09.2014 | Original Article

Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases

verfasst von: P. Sammartino, S. Sibio, D. Biacchi, M. Cardi, P. Mingazzini, M. S. Rosati, T. Cornali, B. Sollazzo, J. Maherfouad Atta, A. Di Giorgio

Erschienen in: International Journal of Colorectal Disease | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A major problem in treating patients with peritoneal spread from colorectal cancer is that at diagnosis wide peritoneal involvement often precludes all curative attempts. A possible solution is to identify those patients at risk for peritoneal metastases and intervene early to prevent locoregional disease spread before it develops and, thus, to improve outcome.

Methods

We analyzed long-term results from a previous study and compared outcomes in 25 patients with advanced colon cancer considered at high risk for peritoneal spread (pT3/pT4 and mucinous or signet ring cell histology) prospectively included and managed with a proactive surgical approach including target organ resection for peritoneal spread plus hyperthermic intraperitoneal chemotherapy (HIPEC) and in 50 retrospectively well-matched controls who underwent standard surgical resection during the same period and in the same hospital by different surgical teams.

Results

At 48 months after the study closed, peritoneal metastases and local recurrence developed significantly less often in proactively managed patients than in controls (4 vs 28 %) (p < 0.03). Patients in the proactive group also survived longer than control patients (median overall survival 59.5 vs 52 months). Despite similar morbidity, Kaplan–Meier survival curves disclosed significantly longer disease-free and overall survival in the proactive than in the control group (p < 0.05 and <0.04).

Conclusions

In patients with advanced colon cancer at risk for peritoneal recurrence, the proactive surgical approach plus HIPEC seems to achieve good locoregional control preventing peritoneal spread thus improving outcome without increasing morbidity. These advantages merit investigation in a multicentric randomized trial.
Literatur
1.
Zurück zum Zitat Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284–3292PubMedCrossRef Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284–3292PubMedCrossRef
2.
Zurück zum Zitat Esquivel J, Elias D, Baratti D et al (2008) Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 98(4):263–267PubMedCrossRef Esquivel J, Elias D, Baratti D et al (2008) Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 98(4):263–267PubMedCrossRef
3.
Zurück zum Zitat Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28(1):63–68PubMedCrossRef Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28(1):63–68PubMedCrossRef
4.
Zurück zum Zitat Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH editor; Peritoneal carcinomatosis: principles of management. Boston Kluwers Academic 359–74 Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH editor; Peritoneal carcinomatosis: principles of management. Boston Kluwers Academic 359–74
5.
Zurück zum Zitat Koh JL, Yan TD, Glenn D et al (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16(2):327–333PubMedCrossRef Koh JL, Yan TD, Glenn D et al (2009) Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 16(2):327–333PubMedCrossRef
6.
Zurück zum Zitat Elias D, Honore C, Dumont F et al (2011) Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 254(2):289–293PubMedCrossRef Elias D, Honore C, Dumont F et al (2011) Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 254(2):289–293PubMedCrossRef
7.
Zurück zum Zitat Honoré C, Goéré D, Souadka A et al (2013) Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol 20(1):183–192PubMedCrossRef Honoré C, Goéré D, Souadka A et al (2013) Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol 20(1):183–192PubMedCrossRef
8.
Zurück zum Zitat Nitsche U, Rosenberg R, Balmert A et al (2012) Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Ann Surg 256(5):763–771PubMedCrossRef Nitsche U, Rosenberg R, Balmert A et al (2012) Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Ann Surg 256(5):763–771PubMedCrossRef
9.
Zurück zum Zitat Sugarbaker PH, Sammartino P, Tentes AA (2012) Proactive management of peritoneal metastases from colorectal cancer: the next logical step toward optimal locoregional control. Colorect Cancer 1:115–123CrossRef Sugarbaker PH, Sammartino P, Tentes AA (2012) Proactive management of peritoneal metastases from colorectal cancer: the next logical step toward optimal locoregional control. Colorect Cancer 1:115–123CrossRef
10.
Zurück zum Zitat Sugarbaker PH (2013) The evolution of treatment for peritoneal metastases. Colorect Cancer 2:189–192CrossRef Sugarbaker PH (2013) The evolution of treatment for peritoneal metastases. Colorect Cancer 2:189–192CrossRef
11.
Zurück zum Zitat Sammartino P, Sibio S, Biacchi D, et al (2012) Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract.2012 Sammartino P, Sibio S, Biacchi D, et al (2012) Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract.2012
12.
Zurück zum Zitat Symonds DA, Vickery AL (1976) Mucinous carcinoma of the colon and rectum. Cancer 37(4):1891–1900PubMedCrossRef Symonds DA, Vickery AL (1976) Mucinous carcinoma of the colon and rectum. Cancer 37(4):1891–1900PubMedCrossRef
13.
Zurück zum Zitat Ogino S, Brahmandam M, Cantor M et al (2006) Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19(1):59–68PubMedCrossRef Ogino S, Brahmandam M, Cantor M et al (2006) Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19(1):59–68PubMedCrossRef
14.
Zurück zum Zitat Mekenkamp LJM, Heesterbeek CJ, Punt CJA et al (2012) Reply letter to: Signet ring cell carcinoma as a potential confounding factor in the analysis of outcomes with colorectal mucinous adenocarcinoma. Eur J Cancer 48:3128–3129CrossRef Mekenkamp LJM, Heesterbeek CJ, Punt CJA et al (2012) Reply letter to: Signet ring cell carcinoma as a potential confounding factor in the analysis of outcomes with colorectal mucinous adenocarcinoma. Eur J Cancer 48:3128–3129CrossRef
15.
Zurück zum Zitat World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO, Geneva, Switzerland World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO, Geneva, Switzerland
16.
Zurück zum Zitat Nelson H, Petrelli N, Carlin A et al (2001) Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 18;93(8):583–596CrossRef Nelson H, Petrelli N, Carlin A et al (2001) Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 18;93(8):583–596CrossRef
17.
Zurück zum Zitat Saxena A, Yan TD, Morris DL (2010) A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 34(1):70–78PubMedCrossRef Saxena A, Yan TD, Morris DL (2010) A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg 34(1):70–78PubMedCrossRef
18.
Zurück zum Zitat Iafrate F, Ciolina M, Sammartino P et al (2012) Peritoneal carcinomatosis: imaging with 64-MDCT and 3 T MRI with diffusion-weighted imaging. Abdom Imaging 37(4):616–627PubMedCrossRef Iafrate F, Ciolina M, Sammartino P et al (2012) Peritoneal carcinomatosis: imaging with 64-MDCT and 3 T MRI with diffusion-weighted imaging. Abdom Imaging 37(4):616–627PubMedCrossRef
20.
Zurück zum Zitat Jayne DG, Fook S, Loi C et al (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89(12):1545–1550PubMedCrossRef Jayne DG, Fook S, Loi C et al (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89(12):1545–1550PubMedCrossRef
21.
Zurück zum Zitat Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clinical Oncol 27(5):681–685CrossRef Elias D, Lefevre JH, Chevalier J et al (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clinical Oncol 27(5):681–685CrossRef
22.
Zurück zum Zitat Kerscher AG, Chua TC, Gasser M et al (2013) Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 108(7):1432–1439PubMedCentralPubMedCrossRef Kerscher AG, Chua TC, Gasser M et al (2013) Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 108(7):1432–1439PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Noura S, Ohue M, Shingai T et al (2011) Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol 18(2):396–404PubMedCrossRef Noura S, Ohue M, Shingai T et al (2011) Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol 18(2):396–404PubMedCrossRef
24.
Zurück zum Zitat Hompes D, Tiek J, Wolthuis A et al (2012) HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol 23(12):3123–3129PubMedCrossRef Hompes D, Tiek J, Wolthuis A et al (2012) HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol 23(12):3123–3129PubMedCrossRef
25.
Zurück zum Zitat Rottoli M, Stocchi L, Dietz DW (2012) T4N0 colon cancer has oncologic outcomes comparable to stage III in a specialized center. Ann Surg Oncol 19(8):2500–2505PubMedCrossRef Rottoli M, Stocchi L, Dietz DW (2012) T4N0 colon cancer has oncologic outcomes comparable to stage III in a specialized center. Ann Surg Oncol 19(8):2500–2505PubMedCrossRef
26.
Zurück zum Zitat Stewart C, Hillery S, Havlat M (2006) Serosal involvement in colorectal carcinoma. Histopathology 49(4):435–437PubMedCrossRef Stewart C, Hillery S, Havlat M (2006) Serosal involvement in colorectal carcinoma. Histopathology 49(4):435–437PubMedCrossRef
27.
Zurück zum Zitat Kojima M, Nakajima K, Ishii G et al (2010) Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. Am J Surg Pathol 34(9):1351–1360PubMedCrossRef Kojima M, Nakajima K, Ishii G et al (2010) Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. Am J Surg Pathol 34(9):1351–1360PubMedCrossRef
28.
29.
Zurück zum Zitat Song W, Wu SJ, He YL et al (2009) Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. Chin Med J 122(13):1486–1491PubMed Song W, Wu SJ, He YL et al (2009) Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. Chin Med J 122(13):1486–1491PubMed
30.
Zurück zum Zitat Lemmens VE, Klaver YL, Verwaal VJ et al (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128(11):2717–2725PubMedCrossRef Lemmens VE, Klaver YL, Verwaal VJ et al (2011) Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 128(11):2717–2725PubMedCrossRef
31.
Zurück zum Zitat Numata M, Shiozawa M, Watanabe T et al (2012) The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease. World J Surg Oncol 10:109PubMedCentralPubMedCrossRef Numata M, Shiozawa M, Watanabe T et al (2012) The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease. World J Surg Oncol 10:109PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Catalano V, Loupakis F, Graziano F et al (2009) Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer 100(6):881–887PubMedCentralPubMedCrossRef Catalano V, Loupakis F, Graziano F et al (2009) Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer 100(6):881–887PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Lee DW, Han SW, Lee HJ et al (2013) Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. Br J Cancer 108(10):1978–1984PubMedCentralPubMedCrossRef Lee DW, Han SW, Lee HJ et al (2013) Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. Br J Cancer 108(10):1978–1984PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Elias D, Goéré D, Dumont F et al (2014) Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 50(2):332–340PubMedCrossRef Elias D, Goéré D, Dumont F et al (2014) Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 50(2):332–340PubMedCrossRef
36.
Zurück zum Zitat Sammartino P, Sibio S, Accarpio F, et al (2014) Prevention of peritoneal carcinomatosis from colorectal cancer: a critical issue. Ann Surg Mar;259 (3) Sammartino P, Sibio S, Accarpio F, et al (2014) Prevention of peritoneal carcinomatosis from colorectal cancer: a critical issue. Ann Surg Mar;259 (3)
37.
Zurück zum Zitat Sugarbaker PH (2000) It’s what the surgeon doesn’t see that kills the patient. J Nippon Med Sch 67(1):5–8PubMedCrossRef Sugarbaker PH (2000) It’s what the surgeon doesn’t see that kills the patient. J Nippon Med Sch 67(1):5–8PubMedCrossRef
Metadaten
Titel
Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases
verfasst von
P. Sammartino
S. Sibio
D. Biacchi
M. Cardi
P. Mingazzini
M. S. Rosati
T. Cornali
B. Sollazzo
J. Maherfouad Atta
A. Di Giorgio
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 9/2014
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-014-1929-4

Weitere Artikel der Ausgabe 9/2014

International Journal of Colorectal Disease 9/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.